Celcuity Shares Decline as Delayed Drug Launch Overshadows First FDA Approval

Shares of Celcuity (CELC) fell approximately 8% in premarket trading on Wednesday, as the positive news of the company's first U.S. Food and Drug Administration (FDA) approval was eclipsed by a delayed product launch and concerns about the drug's tolerability.

FDA Approval and Launch Timeline

The FDA on Tuesday approved gedatolisib, to be marketed as Revtorpyk, for use in certain patients with advanced breast cancer whose tumors lack a PIK3CA mutation. According to a Reuters report, this marks the first approved product for Celcuity.

However, the company stated the commercial launch is not expected until late in the third quarter, citing the need to ensure an adequate drug supply. Leerink Partners analyst Andrew Berens noted this delay was unexpected, given Celcuity's previous statements about its launch readiness.

Efficacy Weighed Against Safety Profile

In a late-stage clinical trial, Revtorpyk, when combined with Pfizer’s Ibrance and fulvestrant, demonstrated significant efficacy. The combination reduced the risk of disease progression or death by 76% compared to fulvestrant alone. Patients on the three-drug regimen experienced a median of 9.3 months without their cancer worsening, versus two months for the control group.

Ad

Despite the strong results, the drug's label includes warnings that have drawn investor attention. Key safety and tolerability data from the trial include:

• 12% of patients discontinued the three-drug treatment due to side effects.
• The label warns of the risk of severe mouth inflammation (stomatitis) and recommends a preventive mouthwash.
• Mouth inflammation occurred in 72% of patients on the combination therapy, with 22% of cases classified as severe.

Market Outlook

The stock's decline suggests investors are weighing the drug's clinical benefits against potential commercial hurdles. Analyst Andrew Berens said Celcuity's ability to help physicians manage the mouth inflammation side effect will be critical to Revtorpyk's commercial success. Needham analyst Gil Blum added that the company plans to price the drug at a premium to currently available therapies, though a specific price was not disclosed.